about
Renal insufficiency and cancer treatmentsRecurrent chimeric fusion RNAs in non-cancer tissues and cells.Cancer and renal insufficiency results of the BIRMA study.[Renovascular safety of bevacizumab in breast cancer patients. The prognostic value of hypertension and proteinuria].Inappropriate drug use and mortality in community-dwelling elderly with impaired kidney function--the Three-City population-based studyProposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients.Pulmonary hypertension: use of oral drugs in patients with renal insufficiency.Malaria prophylaxis in patients with renal impairment: a review.New therapies for hepatitis C: considerations in patients with renal impairment.Prevalence of renal abnormalities in chronic HBV infection: the HARPE study.Management of anticancer treatment in patients under chronic dialysis: results of the multicentric CANDY (CANcer and DialYsis) study.Administration of intravenous iron complexes on implantable central venous access port in cancer patients in France: the FERPAC survey.Renal insufficiency, mortality, and drug management in heart transplant. Results of the CARIN study.Incidence of nephrogenic systemic fibrosis in patients undergoing dialysis after contrast-enhanced magnetic resonance imaging with gadolinium-based contrast agents: the Prospective Fibrose Nephrogénique Systémique study.Lung cancer and renal insufficiency: prevalence and anticancer drug issues.Renal function and venous thromboembolic diseases.Results from the LIDO anemia survey: adherence to EORTC guidelines in cancer patients in France.[Management of targeted therapies in hemodialysis patients].[Renovascular effects of antiangiogenic drugs].Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug managementEvolution of renal function in patients treated with antiangiogenics after nephrectomy for renal cell carcinomaPharmacokinetics and dosage adjustment of oseltamivir and zanamivir in patients with renal failureVaccination and chronic kidney diseaseLetter. Systemic anticancer therapy in gynecological cancer patients with renal dysfunction[Renal insufficiency and breast cancer][Anticancer drugs management in renal insufficiency patients][Management of chemotherapy in hemodialysis patients][Management of analgesics in cancer patients with renal impairment][Renal tolerance of targeted therapies][aMDRD formula is the method of choice for estimating the glomerular filtration rate, even in the "very old": comment on the article by Andro et al][How to adjust the dose of drugs in chronic kidney disease?][Letter on the article: "Kidney and HIV infection"][Reply to the article Non-VKA oral anticoagulants: an update for the clinical biologists]Anticancer Drugs in End-Stage Kidney Disease PatientsAcute renal failure associated with the new BRAF inhibitor vemurafenib: a case series of 8 patients[Drug dosage adjustment in patients with renal impairment and evaluation of renal function: focus on the cardiologic patients]Are Patients with Active Cancer and Those with History of Cancer Carrying the Same Risks of Recurrent VTE and Bleeding While on Anticoagulants?
P50
Q28079168-136B6BB2-A217-466E-9EA8-4B5FB34B1A61Q30277623-ED11C254-AB0F-41C8-A2AB-7344370EA579Q34433767-B80C55FE-71DF-4D58-9AD0-A6833AA8A8AAQ35851751-4B2F6D0B-E2F5-48B9-8EA3-943BD5C94C4AQ37533968-AC235E52-C106-451E-9C73-357BD66ABCF6Q37684587-E1516BA5-C0D8-40B2-861B-58BA66BF81B1Q38066409-3767A317-4C98-4314-8B6E-968A39D3760DQ38078263-2DFA350B-B751-48B6-941C-4972C4A085D3Q38233834-8BC15DFA-5240-4865-9862-933E877E4354Q42238746-9F09AB5E-3BB7-4EBA-AEC9-14FEA5E94438Q43559154-1E3D2ED7-EDCC-4B42-9F6E-AAC6427C133FQ43561167-74F02FA0-4B3C-4828-8655-951D8574542EQ43737109-3A08FE3D-9B80-4BD1-9CA5-929D711EAE98Q44325128-9B913DDC-7409-462F-9370-843DB828021FQ46304694-DA640A01-F034-4627-84C3-D31CFD809149Q48717623-D640D280-5E2C-4D35-A920-7BA80CD26DCCQ48847935-F062F1C6-4406-4F14-A2C1-EA4C97E37DC5Q54546126-C5F5CEA1-D8A7-4417-AEB8-F569232FCE0DQ55021106-F6D54EB4-9A65-4E75-B7F3-5BF993DA6621Q57579648-4C440DAE-B379-4F3D-A317-01BA216B4294Q59152598-01EEC365-7C73-4C7F-A5DB-D16EA98C83D2Q79786603-A80E2895-0A98-477D-B0CE-FA05C121EAB0Q80161999-92A5CF59-E0AD-43CE-A9F6-BB09ADB361A5Q81588815-0CB1A71B-F84C-4FF6-9A25-591639E63EF8Q82623813-DEE56519-FE1B-48B7-9657-78F018E52B76Q82711257-16ACEAF3-4EF8-42BE-9EAE-05CF9DD6D06AQ82765411-D73D654C-81D6-4254-8B94-1760381E9984Q82829723-1988F15A-81FA-4FC1-8C04-F63881617C1BQ82829960-C4C5DA3B-19C2-47DC-873A-DE5B4E9CFB71Q83863523-A32632EE-5E99-42B3-BBAF-AA1DD31B34E0Q83928293-EAC1AAE7-7F28-44D9-9D9C-A5FD8277926AQ84594338-F9E46B26-2BA3-4FA3-B3E2-88EB55B8AE37Q86853138-4C59EDFC-AAF2-4F6E-ACCD-ED9689A30A74Q87098090-AAF3284E-95C6-439B-A1E6-9AE1795A6EC5Q87691575-54C9EF15-8B4C-43AD-9A8E-9F5D035FF3A7Q87938865-FD782003-367A-4B56-982C-7A7BCB4B91D5Q91867487-58BF0D70-F22A-4DF2-B1BB-BC95ADC2E1DD
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Nicolas Janus
@ast
Nicolas Janus
@en
Nicolas Janus
@es
Nicolas Janus
@nl
Nicolas Janus
@sl
type
label
Nicolas Janus
@ast
Nicolas Janus
@en
Nicolas Janus
@es
Nicolas Janus
@nl
Nicolas Janus
@sl
prefLabel
Nicolas Janus
@ast
Nicolas Janus
@en
Nicolas Janus
@es
Nicolas Janus
@nl
Nicolas Janus
@sl
P106
P21
P31
P496
0000-0002-6700-4917